

- 1 -

USE OF CANTHIN-6-ONE, PLANT EXTRACTS CONTAINING SAME
AND DERIVATIVES THEREOF IN THE TREATMENT OF
TRYPANOSOMIASSES

5 The invention relates to the use of canthin-6-one,
plant extracts containing same and some derivatives
thereof for producing a medicinal product intended for
the treatment of trypanosomiasis, in particular for the
treatment of Chagas' disease.

10

In Latin America, approximately 90 million individuals
live in regions where Chagas' disease is endemic.
Approximately 18 to 20 million individuals are already
infected with the agent responsible for this disease:

15 *Trypanozoma (Schizotrypanum) cruzi*.

Chemotherapeutic treatments for this disease are at the
current time based on two families of molecules:
nitrofurans, for instance nifurtimox, and
20 nitroimidazoles, for instance benznidazole. These
compounds can be effective on Chagas' disease at the
beginning of infection, but they are barely effective,
or not at all, on this disease when *Trypanosoma cruzi*
has become established in the organism and the disease
25 has taken on a chronic nature.

At this stage, this disease is at the current time
considered to be incurable.

30 Treatments with nifurtimox and with benznidazole are
also confronted with the appearance of resistant
strains of *Trypanosoma cruzi*, which further decreases
their effectiveness in the primary phase of Chagas'
disease. Finally, these two molecules have not
35 insignificant side effects such as anorexia, vomiting,
peripheral neuropathy and allergic dermatopathy.

There was therefore a need for a treatment for Chagas' disease that is effective both in the first phase of the disease, where *Trypanosoma cruzi* is present essentially in the blood, and in the second phase of this disease, where *Trypanosoma cruzi* is essentially found in the organs: heart, digestive system.

Canthin-6-one is a known compound that was isolated from plants such as: *Ailanthus altissima* (Simaroubaceae) by Ohmoto et al., Chem. Pharm. Bull., 1976, 24, 1532-1536; *Brucea antidysenterica* (Simaroubaceae) by Fukamiya et al., Planta Med., 1987, 53, 140-143; *Eurycoma harmandiana* (Simaroubaceae) by Kachanapoom et al., Phytochemistry, 2001, 56, 383-386; *Peganum nigellastrum* (Zygophyllaceae) by Ma et al., Phytochemistry, 2000, 53, 1075-1078.

Canthin-6-one has been identified in an extract of *Zanthoxylum elephantiasis* (Rutaceae) by Mitscher et al., Lloydia, 1972, 35, 177-180.

Therapeutic activities of canthin-6-one or of plant extracts containing it have been reported in the following indications:

The treatment of malaria, by Kordona et al., J. Nat. Prod., 1991, 54(5), 1360-1367; as an antitumor agent, by Fukamiya et al., Planta Med., 1987, 53(2), 140-143; as an antifungal agent by Mitscher et al., Lloydia, 1972, 35(2), 177-180.

Zanthoxylum chiloperone, from where the canthin-6-one for the use of the invention is extracted, is known for its use in traditional medicine as an anti-inflammatory, as an antipyretic, against rheumatism, and as a general antiparasitic.

However, nothing in the prior art implied that canthin-6-one was capable of constituting a treatment for

Chagas' disease, both in its primary or acute phase and in its chronic phase.

5 A subject of the invention is therefore the use of canthin-6-one, of plant extracts containing it and of some of its derivatives, which will be defined below, for producing a medicinal product intended for the treatment of trypanosomiasis, in particular the treatment of Chagas' disease.

10

Canthin-6-one was isolated from the bark of the trunk of a rutacea identified as *Zanthoxylum chiloperone* var. *angustifolium*.

15 This plant was harvested in Paraguay, close to Piribebuy in the department of Cordillera. An example of this plant was registered with the Herbarium of the Faculty of Chemistry of Asuncion in Paraguay under the number AF917.

20

Several extracts of *Zanthoxylum chiloperone* var. *angustifolium* were isolated by means of a method that will be described below. Canthin-6-one itself was also isolated from this plant. However, the invention can
25 also be implemented using canthin-6-one isolated from the other plants that contain it, and that were listed above. Extracts of *Ailanthus altissima*, of *Brucea antidysenterica*, of *Eurycoma harmandiana*, of *Peganum nigellastrum* or of *Zanthoxylum elephantiasis* that
30 contain it can also be used to implement the invention.

According to a preferred embodiment of the invention, the extraction of *Zanthoxylum chiloperone* var. *angustifolium* and the isolation of the canthin-6-one
35 were carried out according to a method comprising a first step that consists in grinding the dried bark of the trunk of *Zanthoxylum chiloperone* var. *angustifolium* and then in treating it with an aqueous alkaline solution, for instance with an aqueous ammonia

solution.

The mixture obtained is extracted with a chlorinated organic solvent, for instance dichloromethane.

5

The canthin-6-one can then be isolated and purified by means well known to those skilled in the art, such as extraction, washing, chromatography, precipitation or recrystallization.


10

The same method or a similar method can be used on other plants containing canthin-6-one, in order to obtain extracts thereof comprising canthin-6-one or to isolate this compound.

15

Other compounds derived from canthin-6-one can be isolated from the plants mentioned above by similar methods. Canthin-6-one derivatives can also be prepared by methods of synthesis well known to those skilled in the art, using canthin-6-one or any other suitable compound as starting product. In particular, the invention relates to the derivatives corresponding to formula (I) below, and to their use for producing a medicinal product intended for the treatment of trypanosomiasis:

25



In formula (I), R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 and R_8 represent, independently of one another:

- a hydrogen atom

- a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group,
- a halogen atom chosen from chlorine, fluorine, bromine and iodine,
- 5 • a halo(C₁-C₁₂)alkyl group in which the alkyl chain may be linear, branched or cyclic, and saturated or unsaturated, and the halogen atom(s) is (are) chosen from fluorine, chlorine, bromine and iodine,
- 10 • a hydroxyl function,
- a nitro function -NO,
- a cyano function -CN,
- a function -SH,
- a carboxylic acid function -COOH,
- 15 • an amide function -CONH₂,
- an amine function -NH₂,
- a C₁-C₁₂ alkoxy function in which the alkyl group may be linear, branched or cyclic, and saturated or unsaturated,
- 20 • a C₁-C₁₂ alkyl ester function, in which the alkyl group may be linear, branched or cyclic, and saturated or unsaturated,
- a secondary or tertiary alkylamide function, in which the C₁-C₁₂ alkyl group(s) may be linear, branched or cyclic, and saturated or unsaturated,
- 25 • a secondary or tertiary alkylamine function, in which the C₁-C₁₂ alkyl group(s) may be linear, branched or cyclic, and saturated or unsaturated,
- a C₁-C₁₂ alkylthio function, in which the alkyl group may be linear, branched or cyclic, and saturated or unsaturated,
- 30 • a C₂-C₆ heterocyclic group containing 1 to 4 hetero atoms chosen from sulfur, nitrogen and oxygen,
- a group -SO₂-NR'R'' or a group -NR'-SO₂-R'', in which R' and R'' represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;
- 35 n represents 0 or 1;
- R represents a saturated or unsaturated, linear,

branched or cyclic C₁-C₁₂ alkyl group;

X⁻ represents an anion that can be chosen from inorganic or organic anions such as, for example, the Cl⁻ ion, the Br⁻ ion, the I⁻ ion, the S⁻ ion, the PO₃⁻ ion, the NO₃⁻ ion, the acetate ion, the oxalate ion, the tartrate ion, the succinate ion, the maleate ion, the fumarate ion, the gluconate ion, the citrate ion, the malate ion, the ascorbate ion and the benzoate ion.

10

Canthin-6-one corresponds to formula (I) in which:

R₁ = R₂ = R₃ = R₄ = R₅ = R₆ = R₇ = R₈ = H and n = 0.

15 A subject of the invention is therefore a compound corresponding to formula (I) as defined above, in which at least one of R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ is different from H or else in which n = 1.

20 A subject of the invention is also a medicinal product comprising a compound corresponding to formula (I) as defined above, in which at least one of R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ is different from H, or else in which n = 1, in a pharmaceutically acceptable support.

25 Preferably, a subject of the invention is one of the compounds of formula (I) in which one or more of the conditions below are satisfied:

- 30 - R₃ represents an NH₂ group or a C₁-C₁₂ alkylamine group or a C₁-C₁₂ alkylamide group or a C₂-C₆ heterocycle comprising at least one amine function;
- R₄ represents a hydroxyl group or a C₁-C₁₂ alkoxy group;
- 35 - R₁ = R₂ = R₅ = R₆ = R₇ = R₈ = H.

Even more preferably, a subject of the invention is one of the compounds of formula (I) in which one or more of the conditions below are satisfied:

- R₃ represents an NH₂ group or a C₁-C₆ alkylamine group or a C₁-C₆ alkylamide group or a C₂-C₆ heterocycle comprising at least one amine function;
5
 - R₄ represents a hydroxyl group or a C₁-C₆ alkoxy group;
 - R₁ = R₂ = R₅ = R₆ = R₇ = R₈ = H.
- 10 Even more preferably, a subject of the invention is one of the compounds of formula (I) in which one or more of the conditions below are satisfied:
- R₃ represents an NH₂ group;
 - 15 - R₄ represents an OCH₃ group;
 - R₁ = R₂ = R₅ = R₆ = R₇ = R₈ = H.

According to another preferred variant of the invention, the compound of the invention is chosen from
20 the compounds of formula (I) in which R₁ = R₂ = R₃ = R₄ = R₅ = R₆ = R₇ = R₈ = H and n = 1. According to this variant, R is advantageously a C₁-C₆ alkyl group. Even more advantageously, R is chosen from methyl and ethyl groups.


25 Advantageously, the compound of formula (I) is chosen from:

- 4-aminocanthin-6-one;
- 30 - N-methylcanthin-6-one iodide;
- 5-methoxycanthin-6-one.

The molecules of the invention can be obtained by following one of the synthetic pathways summarized in
35 the schemes below. The preparation examples given in the experimental section also illustrate pathways for obtaining these compounds. The adaptation of these synthetic pathways to the various products corresponding to formula (I) calls upon the general


knowledge of those skilled in the art.

Scheme 1:




- 5 **Legend:** (a) substituted succinic anhydride; (b) formation of substituted oxazoles; (c) aza-Diels-Alder reaction; (d) dehydration; (e) oxidation of the 4-5 linkage.

10 Scheme 2:



- Legend:** (a) see example 2 below; (b) modifications of the primary amine function.

15 Scheme 3:



- Legend:** (a) oxidation to quinone; (b) reduction; (c) derivatizations or modifications of the hydroxyls.

- 20 Two forms of trypanosomiases are known, one is caused by the agent *Trypanosoma brucei* and is more well known under the name sleeping sickness, the other is caused by the agent *Trypanosoma cruzi* and is known as Chagas' disease. The invention is preferentially interested in
- 25 the preparation of an effective treatment against *Trypanosoma cruzi*.

In the activity assays that are disclosed in detail below, canthin-6-one showed surprising effectiveness against *Trypanosoma cruzi*, in particular at doses ten
5 times lower than the doses at which benznidazole is effective.

According to the invention, canthin-6-one, plant
extracts containing it, or canthin-6-one derivatives,
10 such as those corresponding to formula (I) defined above, will be used for treating infected individuals with trypanosomiasis, in particular for treating individuals infected with *Trypanosoma cruzi*, at a dose of between 0.01 and 100 mg/kg/d of canthin-6-one or of
15 a derivative of formula (I), preferably of between 0.1 and 50 mg/kg/d, even more preferably of between 1 and 20 mg/kg/d.

Advantageously, the treatment will be formulated in the
20 form of daily doses comprising from 0.2 mg to 1 g of canthin-6-one or of a derivative of formula (I), preferably from 2 to 500 mg, even more preferably from 5 to 200 mg.

25 The canthin-6-one, the plant extracts containing it and its derivatives of formula (I) can be administered orally or parenterally, combined with any appropriate pharmaceutical carrier. Preferably, the canthin-6-one, the plant extracts containing it and its derivatives of
30 formula (I) are administered orally.

The invention will be understood more clearly from the following examples intended to illustrate it.

35 **EXAMPLES:**

Materials and methods

The UV spectra were obtained on a Philips PU 8720


spectrometer. The IR spectra were measured on a Perkin-Elmer 257 spectrometer in KBr pellets. The ^1H and ^{13}C NMR spectra (CDCl_3) were obtained on a Bruker AC-200 or AC-400 device at a frequency of 200 and 50 MHz, respectively, or of 400 and 100 MHz, respectively. The EIMS and CIMS (methane) were measured on a Nermag R10-10C spectrometer. The semi-preparative HPLC was carried out using Waters 590 detector connected to an ABB SE 120 recording device, with a Millipore-Waters system (Milford MA, USA) equipped with a 590 pump, an SSV injector and a Millipore C_{18} Prepak 1000 column.

Example 1: Isolation of canthin-6-one and of 5-methoxycanthin-6-one:

The *Zanthoxylum chiloperone* bark extraction method is represented in figure 1:

The dried bark of the trunk of *Zanthoxylum chiloperone* (1.9 kg) is treated with dichloromethane in a Soxhlet device, so as to give, after evaporation of the solvent, 44 g of plant extract. This extract is redissolved and then purified by flash chromatography on a silica column using an ethyl acetate/dichloromethane (8:2) mixture as eluent. 9 fractions, each of 250 ml, numbered 1 to 9 in the order of elution, are recovered. Fractions f_{3b} to f_5 are combined to give 3.2 g of canthin-6-one after evaporation of the solvents and crystallization from acetone.

Fraction f_6 is purified by preparative HPLC using as solvent a mixture of methanol and water (7:3), to give 150 mg of 5-methoxycanthin-6-one after crystallization from acetone.



Canthin-6-one

$C_{14}H_8N_2O$: 220

The canthin-6-one crystallizes from acetone in the form of pale yellow needles.

5

The melting point (Mp), determined on a Köflier bench, is 162°C.

UV spectrum: MeOH_{max} nm (log ε) (in MeOH at 0.05 g/l):

10 225 (1.70), 251 (1.35), 260 (1.40), 268 (1.40), 362 (1.33), 379 (1.29); (+0.5N HCl): 225 (non-determinable), 266 (1.49), 273 (1.49), 304 (1.56), 360; (+1N NaOH): 225 (non-determinable) 251 (1.54), 259 (1.55), 267 (1.50), 362 (1.33), 379 (1.29).

15 **IR spectrum:** 1665, 1630 cm⁻¹

¹H NMR spectrum: 400 MHz (CDCl₃)_ppm: 6.90 (d, 1H, *J* = 9.8 Hz, H₅); 7.50 (td, 1H, *J* = 8.5; 7.5 and 1 Hz, H₁₀); 7.70 (td, 1H, *J* = 8.2; 8.5 and 1 Hz, H₉); 7.90 (d, 1H, *J* = 5 Hz, H₁); 8.00 (d, 1H, *J* = 9.8 Hz, H₄); 8.10 (dt, 1H, *J* = 7.5 and 1 Hz, H₁₁); 8.65 (dt, 1H, *J* = 8.2 and 1 Hz, H₈); 8.80 (d, 1H, *J* = 5 Hz, H₂).

¹³C NMR spectrum: 50 MHz (CDCl₃)_ppm: 116.4 (C₁H), 117.2 (C₈H), 122.6 (C₁₁H), 124.3 (C₁₂), 125.7 (C₁₀H), 129.0 (C₅H), 130.1 (C₁₃), 130.7 (C₉H), 131.9 (C₁₄), 136.2 (C_{3a}), 139.3 (C_{7a}), 139.6 (C₄H), 145.9 (C₂H), 159.0 (C₆).


Mass spectrum: [ion fragment] *m/z* (%) [M+Na]⁺: 243 (100%).

Elemental Analysis: C: 76.42; H: 3.68; N: 12.86%.

Example 2: Process of synthesizing canthin-6-one derivatives

▪ **4-aminocanthin-6-one:**

5




C₁₄H₉N₃O - MW 235

10 The canthin-6-one (100 mg - 0.45 mmol) is suspended in a saturated solution of sodium azide (50 ml). Dimethylformamide is added until a clear solution is obtained. An excess of zinc bromide is added (1 g) and the medium is brought to reflux until the starting product has been consumed (reaction followed by thin
15 layer chromatography, 9:1 CH₂Cl₂/MeOH). The cooled reaction medium is greatly diluted with water and then extracted with dichloromethane (4 times). The combined organic phases are dried (Na₂SO₄) and then concentrated under reduced pressure. The 4-aminocanthin-6-one is
20 purified by flash chromatography on a silica column (0.3 bar, elution: 95:5 CH₂Cl₂/MeOH), 74 mg (70%).

A powdery yellow solid is obtained: ¹H NMR spectrum (400 MHz, CDCl₃): δ ppm, 4.9 (s, 2H); 7.0 (s, 1H); 7.5 (t, J = 7.6 Hz, 1H); 7.7 (m, 2H); 8.05 (d, J = 7.6 Hz 1H); 8.65 (d, J = 8.1 Hz, 1H); 8.7 (d, J = 5.1 Hz, 1H); ¹³C NMR spectrum (100 MHz, CDCl₃): δ ppm, 106.8; 112.0; 117.0; 122.6; 125.7; 125.8; 126.5; 129.1; 130.1; 138.8; 139.1; 142.4; 145.9; 156.2; infrared spectrum (ν, cm⁻¹): 3254, 1673, 1612, 1580, 1556, 1443, 1333, 1313; mass spectrum (electrospray, m/z): 236 [M+H⁺]; Mp (CH₂Cl₂): 199-200°C; R_f = 0.6 (9:1 CH₂Cl₂/MeOH).
25
30

▪ **N-methylcanthin-6-one iodide**



C₁₅H₁₁IN₂O - MW 362

5 The canthin-6-one (100 mg - 0.45 mmol) is dissolved in
methyl iodide (1 ml). The solution is stirred at
ambient temperature until the starting product has been
consumed (reaction followed by thin layer
chromatography, 9:1 CH₂Cl₂/MeOH). The precipitate is
10 collected by filtration and washed with dichloromethane
(150 mg - 90%).

An orange powder is obtained, ¹H NMR spectrum (400 MHz,
DMSO-d₆): δ ppm, 4.6 (s, 3H); 7.4 (d, J = 10.0 Hz, 1H);
15 7.7 (t, J = 7.7 Hz, 1H); 8.0 (t, J = 7.8 Hz, 1H); 8.6 (m,
3H); 8.9 (d, J = 6.3 Hz, 1H); 9.1 (d, J = 6.3 Hz, 1H); ¹³C
NMR spectrum (100 MHz, CDCl₃): δ ppm, 44.3; 116.8; 119.1;
122.5; 125.7; 127.4; 127.5; 130.2; 133.3; 133.7; 134.7;
136.1 141.4; 142.7; 158.0; infrared spectrum (ν, cm⁻¹):
20 1684, 1655, 1340, 1257, 1142; mass spectrum (electrospray,
m/z): 235 [M⁺]; Mp (CH₂Cl₂): 240°C.

**Example 3: Methodology of the in vivo trials on
Trypanosoma cruzi in the acute phase:**

25 Animals and parasites: The Balb/c-type mice are bred in
the animal house of the Health Sciences Research
Institute (IICS, Asuncion, Paraguay) and are 6 to 8
weeks old at the time of the experimental protocols.

30 For these trials, the CL strain (Brener clone) of *T.*
cruzi is used in the circulating form of the parasite
(trypomastigotes). The animals are infected
intraperitoneally with 5000 parasites; this strain
35 produces its parasite peak 21 to 25 days after

infection. Each week, the number of parasites is verified by means of a blood sample taken from the tail of the mouse.

5 Infection and treatment: The treatments with benznidazole, the reference medicinal product, and canthin-6-one begin 11 days after parasitic infection, at a rate of 50 mg/kg or 200 mM/kg for benznidazole and at the concentration of 5 mg/kg or 20 mM/kg for
10 canthin-6-one. The duration of the treatments is fixed at two weeks and the chosen route of administration is oral for benznidazole and canthin-6-one; furthermore, a group of mice is treated with canthin-6-one administered subcutaneously. The untreated and infected
15 mice are given 100 µl of a phosphate buffered saline solution.

Criteria for evaluating treatment effectiveness:

20 - weekly counting of the number of parasites circulating in the peripheral blood throughout the experiment, i.e. 10 weeks;
- observation of mortality;
- two serological evaluations: 40 days post-
25 infection, i.e. 15 days after treatment has been stopped, and 68 days post-infection, i.e. 45 days post-treatment. The serological evaluation is carried out by means of a Chagas ELISA assay (enzyme linked immunoassay) kit, IISC, Asuncion. The optical densities
30 are measured with an ELISA plate reader (Titerek, Unistan, I).

Statistical studies: The mean and the standard deviations of each group are calculated, the
35 differences between the groups are determined by means of the Student's test and the Kruskal-Wallis non-parametric analysis of variance test. The comparisons are carried out between the nontreated group and the treated groups, $P < 0.05$.

The results are given in Tables I and II and in Figures 2, 3 and 4.

5 **TABLE I**

Effectiveness of canthin-6-one and of benznidazole on mice infected experimentally with *Trypanosoma cruzi*
Parasitological evaluation (number of parasites \pm standard deviation)

10

Days post-infection	Untreated controls (n = 8)	Benznidazole (n = 8)	Oral canthin-6-one (n = 7)	Subcutaneous canthin-6-one (n=8)
4	0	0	0	0
11*	90.9 \pm 257	0	0	0
18*	313.6 \pm 468.7	34.9 \pm 98.6	285 \pm 515.9	766.3 \pm 719.2
25*	387.3 \pm 671.1	250.1 \pm 503.5	402 \pm 837.7	88.4 \pm 142.9
32	242.1 \pm 553.2	296.8 \pm 625.5	426.2 \pm 664.5	267.5 \pm 546.5
39	870.5 \pm 1902.1	118.3 \pm 192.9	36.6 \pm 58.4	2077.1 \pm 2214.2
45	835.8 \pm 1002.7	300.8 \pm 431.6	34.4 \pm 76.9 P = 0.05	314.1 \pm 499.3
53	1273.3 \pm 1647.8	23.3 \pm 65.8 P = 0.01	58.4 \pm 80.6 P = 0.05	473.4 \pm 921.9
60	1050.1 \pm 2605.5	65.3 \pm 93.2	16 \pm 35.8 P < 0.05	129.9 \pm 194.4
68	1144.1 \pm 1641.9	9.4 \pm 26.5 P = 0.03	0 P = 0.02	34.9 \pm 98.6 P = 0.03

* Period of treatment (two weeks)

n = number of mice

TABLE II:

Effect of the treatment with canthin-6-one or of
5 benznidazole on Balb/c mice infected with *T. cruzi*
Serological evaluation (ELISA assay)

Treatment	No. of mice	Route of admin.	1st serology®	Negative serology/ survivor	2nd serology ∇	Negative serology/ survivor
Untreated controls (PBS)	8	Oral	0.3985 ± 0.092	0/8 (0%)	0.1598 ± 0.382.3	0/8 (0%)
Benznidazole (reference medicinal product) (50 mg)	8	Oral	0.1692 ± 0.1179 P < 0.001	6/8 (75%)	0.7934 ± 0.8607 P < 0.05	3/8 (37.5%)
Canthin-6- one (5 mg)	7	Oral	0.1105 ± 0.0387 P < 0.001	7/7 (100%)	0.3953 ± 0.7531 P < 0.05	3/7 (42.9%)
Canthin-6- one (5 mg)	8	SC	0.2151 ± 0.1447 P < 0.05	4/7 (57.1%)	0.1347 ± 0.6327 P < 0.001	2/6 (33.3%)

Serology: anti-*T. cruzi* ELISA.

® 40 days post-infection; 15 days post-treatment

10 ∇ 68 days post-infection; 45 days post-treatment

Value of *P* versus untreated controls.

As can be seen in Figure 2, canthin-6-one administered orally at a dose of 5 mg/kg/d shows, from the 39th day
15 after infestation and 15 days after the end of treatment, an activity that is much greater than the benznidazole used at the dose of 50 mg/kg/d. It allows complete eradication of *Trypanosoma cruzi* from the infected organism, something which benznidazole does
20 not make it possible to obtain. These results are

confirmed by the optical density measurement (ELISA) at 15 and 48 days after the end of treatment, as is illustrated in Figures 3 and 4.

5 **Example 4: Methodology of the in vivo trials on Trypanosoma cruzi in the chronic phase**

Animals and parasites:

10 The Balb/c-type mice are bred in the animal house of the Health Sciences Research Institute (IICS, Asuncion, Paraguay) and are 6 to 8 weeks old at the time of the experimental protocols. For this experimental protocol, the CL strain (Brener clone) of *T. cruzi* is used in the
15 circulating form (trypomastigotes), and the strain is maintained in routine culture on an animal model by passage every 14 days. The animals are infected intraperitoneally with 1000 parasites. Under these experimental conditions, the parasites develop slowly;
20 this strain produces a parasite peak 21 to 28 days after infection. The majority of the mice survive (70-80%) with slight deterioration of their general physical condition and with absent or subpatent parasitemia. Each week, the number of parasites is
25 verified by taking a blood sample from the tail of the mouse.

Infection and treatments:

30 For this long-duration experiment, the treatments begin 120 days after parasitic infection, when the parasitemia is subpatent in all the mice. The mice are then divided up into groups randomly. The treatments with benznidazole, the reference medicinal product, are
35 administered at a concentration of 50 mg/kg or 200 mM/kg per day for 20 days, orally. Canthin-6-one is administered either orally or subcutaneously at a concentration of 5 mg/kg or 20 mM/kg per day for 20 days. A total dichloromethane extract of *Zanthoxylum*

chiloperone var. *angustifolium* trunk bark is administered orally or subcutaneously at a concentration of 50 mg/kg per day for 20 days. For administration, the active principles are dissolved in 50 µl of a phosphate buffered saline (PBS) solution. The untreated and infected mice receive 50 µl of PBS.

Criteria for evaluating treatment effectiveness:

- 10 - Weekly counting of the number of parasites circulating in the peripheral blood throughout the experiment, i.e. 30 weeks.
- Observation of mortality.
- Three serological evaluations, 45 days before the beginning of treatments, 10 days after treatment has stopped and 75 days post-treatment. The serological evaluation is carried out using a Chagas ELISA assay (enzyme linked immunoassay) kit, IISC, Asuncion. The optical densities are measured with an ELISA plate reader (Titerek, Unistan, I).

Statistical studies:

- 25 The mean and the standard deviations of each group are calculated, and the differences between the groups are determined by means of the Student's test and the Kruskal-Wallis non-parametric analysis of variance test. The comparisons are carried out between the untreated group and the treated groups, $P < 0.05$.

The results are given in Tables III and IV.

TABLE III

35

Parasitological therapies in mice infected chronically with *T. cruzi* and treated for 20 days with benznidazole ($n = 5$), canthin-6-one ($n = 8$) and a total extract of *Zanthoxylum chiloperone* var. *angustifolium* ($n = 7$)

Treatment*	Negative parasitemia/number of surviving mice (number of days post-treatment)			
	0	10 d	40 d	60 d
Untreated control mice	5/5	2/4	1/1	1/1
Benznidazole (50 mg/kg/d) orally	5/5	2/5	5/5	5/5
Canthin-6-one (5 mg/kg) orally	7/8	7/8	8/8	8/8
Canthin-6-one (5 mg/kg/d) subcutaneously	6/8	7/8	6/8	6/8
Total extract of <i>Z. chiloperone</i> bark (50 mg/kg/d) orally	7/7	7/7	7/7	7/7
Total extract of <i>Z. chiloperone</i> bark (50 mg/kg/d) subcutaneously	4/6	4/6	5/5	3/5

* Treatments 108 days after parasitic infection

Table IV

5

Effect of treatment with canthin-6-one, a total extract of *Zanthoxylum chiloperone* var. *angustifolium*, or benznidazole on Balb/c mice chronically infected with *T. cruzi*.

10

Treatment	ELISA (optical density \pm standard deviation) Number of days post-treatment		
	43 days before treatment	10 d	75 d
Untreated control mice	1.805 \pm 0.075	1.913 \pm 0.115	1.793*


Benznidazole (50 mg/kg/d) orally	2.072 ± 0.220	1.712 ± 0.473	1.979 ± 0.350
Canthin-6-one (5 mg/kg) orally	1.878 ± 0.348	1.621 ± 0.547	1.799 ± 0.333
Canthin-6-one (5 mg/kg/d) subcutaneously	1.916 ± 0.368	1.850 ± 0.405	1.870 ± 0.268
Total extract of <i>Z. chiloperone</i> bark (50 mg/kg/d) orally	1.932 ± 0.228	1.890 ± 0.288	1.961 ± 0.172
Total extract of <i>Z. chiloperone</i> bark (50 mg/kg/d) subcutaneously	1.718 ± 0.264	1.703 ± 0.470	1.815 ± 0.374

* just one mouse alive at the end of the experiment

As can be seen in Table III, canthin-6-one administered orally, at a dose of 5 mg/kg/d for 20 days from the 108th day after parasitic infection, and 79 days after the end of the treatment, showed greater activity than benznidazole used at a dose of 50 mg/kg/d. It induces complete eradication of *Trypanosoma cruzi* from the infected organism and protects the mice against death. These results are confirmed by serology using the ELISA assay, at 10 and 75 days after the end of treatment, as is illustrated by the data in Table IV.

CLAIMS

1. The use, for producing a medicinal product intended for the treatment of trypanosomiasis, of a
 5 compound corresponding to formula (I):



(I)

in which R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ represent, independently of one another:

- 10 • a hydrogen atom
- a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group,
- a halogen atom chosen from chlorine, fluorine, bromine and iodine,
- 15 • a halo(C₁-C₁₂)alkyl group in which the alkyl chain may be linear, branched or cyclic, and saturated or unsaturated, and the halogen atom(s) is (are) chosen from fluorine, chlorine, bromine and iodine,
- 20 • a hydroxyl function,
- a nitro function -NO,
- a cyano function -CN,
- a function -SH,
- a carboxylic acid function -COOH,
- 25 • an amide function -CONH₂,
- an amine function -NH₂,
- a C₁-C₁₂ alkoxy function in which the alkyl group may be linear, branched or cyclic, and

- saturated or unsaturated,
- a C₁-C₁₂ alkyl ester function, in which the alkyl group may be linear, branched or cyclic, and saturated or unsaturated,
 - 5 • a secondary or tertiary alkylamide function, in which the C₁-C₁₂ alkyl group(s) may be linear, branched or cyclic, and saturated or unsaturated,
 - 10 • a secondary or tertiary alkylamine function, in which the C₁-C₁₂ alkyl group(s) may be linear, branched or cyclic, and saturated or unsaturated,
 - 15 • a C₁-C₁₂ alkylthio function, in which the alkyl group may be linear, branched or cyclic, and saturated or unsaturated,
 - a C₂-C₆ heterocyclic group containing 1 to 4 hetero atoms chosen from sulfur, nitrogen and oxygen,
 - 20 • a group -SO₂-NR'R'' or a group -NR'-SO₂-R'', in which R' and R'' represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;
n represents 0 or 1;
R represents a saturated or unsaturated,
25 linear, branched or cyclic C₁-C₁₂ alkyl group;
X⁻ represents an anion that can be chosen from inorganic or organic anions.

2. The use as claimed in claim 1, characterized in
30 that the compound of formula (I) is canthin-6-one.

3. The use of canthin-6-one for producing a medicinal product intended for the treatment of trypanosomiasis as claimed in claim 2,
35 characterized in that the canthin-6-one is present in the form of a plant extract.

4. The use as claimed in claim 3, characterized in that the canthin-6-one is present in the form of

an extract of a plant chosen from: *Ailanthus altissima*, *Brucea antidysenterica*, *Eurycoma harmandiana*, *Peganum nigellastrum*, *Zanthoxylum elephantiasis* and *Zanthoxylum chiloperone*.

5

5. The use as claimed in claim 4, characterized in that the canthin-6-one is present in the form of an extract of *Zanthoxylum chiloperone* var. *angustifolium*.

10

6. The use as claimed in any one of claims 1 to 5, for producing a medicinal product intended for the treatment of trypanosomiasis in its chronic phase and its acute phase.

15

7. The use as claimed in any one of claims 1 to 5, for producing a medicinal product intended for the treatment of Chagas' disease.

20

8. The use as claimed in any one of the preceding claims 1 to 6, characterized in that it is intended for the treatment of trypanosomiasis caused by the agent *Trypanosoma brucei*.

25

9. The use as claimed in any one of the preceding claims 1 to 7, characterized in that it is intended for the treatment of trypanosomiasis caused by the agent *Trypanosoma cruzi*.

30

10. The use as claimed in claim 5, characterized in that the plant extract containing the canthin-6-one is obtained by means of a method comprising a first step that consists in grinding the dried bark of the trunk of *Zanthoxylum chiloperone* var. *angustifolium*, and then in treating it with an aqueous alkaline solution.

35


11. The use as claimed in claim 10, characterized in that the plant extract containing the canthin-6-

one is obtained by means of a method comprising a second step consisting of extraction with a chlorinated organic solvent.

5 12. The use as claimed in any one of the preceding claims 1 to 11, characterized in that the medicinal product is intended to be administered at a dose of between 0.01 and 100 mg/kg/d of compound of formula (I), preferably between 0.1 and 50 mg/kg/d, even more preferably between 1 and 20 mg/kg/d.

13. The use as claimed in any one of the preceding claims, characterized in that the medicinal product is intended to be administered orally.

14. A compound corresponding to formula (I):



20 in which R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ represent, independently of one another:

- a hydrogen atom
- a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group,
- a halogen atom chosen from chlorine, fluorine, bromine and iodine,
- a halo(C₁-C₁₂)alkyl group in which the alkyl chain may be linear, branched or cyclic, and saturated or unsaturated, and the halogen atom(s) is (are) chosen from fluorine,

- chlorine, bromine and iodine,
- a hydroxyl function,
 - a nitro function -NO,
 - a cyano function -CN,
 - 5 • a function -SH,
 - a carboxylic acid function -COOH,
 - an amide function -CONH₂,
 - an amine function -NH₂,
 - a C₁-C₁₂ alkoxy function in which the alkyl
 - 10 group may be linear, branched or cyclic, and saturated or unsaturated,
 - a C₁-C₁₂ alkyl ester function, in which the alkyl group may be linear, branched or cyclic, and saturated or unsaturated,
 - 15 • a secondary or tertiary alkylamide function, in which the C₁-C₁₂ alkyl group(s) may be linear, branched or cyclic, and saturated or unsaturated,
 - a secondary or tertiary alkylamine function,
 - 20 in which the C₁-C₁₂ alkyl group(s) may be linear, branched or cyclic, and saturated or unsaturated,
 - a C₁-C₁₂ alkylthio function, in which the alkyl group may be linear, branched or
 - 25 cyclic, and saturated or unsaturated,
 - a C₂-C₆ heterocyclic group containing 1 to 4 hetero atoms chosen from sulfur, nitrogen and oxygen,
 - a group -SO₂-NR'R'' or a group -NR'-SO₂-R'', in
 - 30 which R' and R'' represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl group;
 - n represents 0 or 1;
 - R represents a saturated or unsaturated,
 - 35 linear, branched or cyclic C₁-C₁₂ alkyl group;
 - X⁻ represents an anion that can be chosen from inorganic or organic anions,
- at least one of R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ being different from H, or else n = 1.

15. The compound as claimed in claim 14, characterized in that X^- is chosen from: the Cl^- ion, the Br^- ion, the I^- ion, the S^- ion, the PO_3^- ion, the NO_3^- ion, the acetate ion, the oxalate ion, the tartrate ion, the succinate ion, the maleate ion, the fumarate ion, the gluconate ion, the citrate ion, the malate ion, the ascorbate ion and the benzoate ion.
16. The compound as claimed in claim 14 or claim 15, characterized in that one or more of the conditions below are satisfied:
- R_3 represents an NH_2 group or a C_1-C_{12} alkylamine group or a C_1-C_{12} alkylamide group or a C_2-C_6 heterocycle comprising at least one amine function;
 - R_4 represents a hydroxyl group or a C_1-C_{12} alkoxy group;
 - $R_1 = R_2 = R_5 = R_6 = R_7 = R_8 = H$.
17. The compound as claimed in any one of claims 14 to 16, characterized in that one or more of the conditions below are satisfied:
- R_3 represents an NH_2 group or a C_1-C_6 alkylamine group or a C_1-C_6 alkylamide group or a C_2-C_6 heterocycle comprising at least one amine function;
 - R_4 represents a hydroxyl group or a C_1-C_6 alkoxy group;
 - $R_1 = R_2 = R_5 = R_6 = R_7 = R_8 = H$.
18. The compound as claimed in any one of claims 14 to 17, characterized in that one or more of the conditions below are satisfied:
- R_3 represents an NH_2 group;
 - R_4 represents an OCH_3 group;
 - $R_1 = R_2 = R_5 = R_6 = R_7 = R_8 = H$.

19. The compound as claimed in any one of claims 14 to 18, characterized in that $R_1 = R_2 = R_3 = R_4 = R_5 = R_6 = R_7 = R_8 = H$ and $n = 1$, and R is a C_1 - C_6 alkyl group.
- 5 20. The compound as claimed in any one of claims 14 to 18, characterized in that it is chosen from:
- 4-aminocanthin-6-one;
 - N-methylcanthin-6-one iodide;
 - 10 - 5-methoxycanthin-6-one.
21. A medicinal product, characterized in that it comprises a compound as claimed in any one of claims 14 to 20, in a pharmaceutically acceptable support.
- 15

"Scheme for extraction of *Zanthoxylum chiloperone* (Rutaceae) bark




FIGURE 1

2/3

Effectiveness of canthin-6-one and of benznidazole on mice experimentally infected with *Trypanosoma cruzi*




FIGURE 2

Effect of treatment with canthin-6-one or benznidazole on Pearl Bright mice infected with *T. cruzi*. Serological evaluation (ELISA assay)




FIGURE 3




FIGURE 4